O5O Stock Overview
Provides healthcare and wellbeing products primarily in Sweden and Finland. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Oriola Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.90 |
| 52 Week High | €1.15 |
| 52 Week Low | €0.88 |
| Beta | 0.61 |
| 11 Month Change | -2.61% |
| 3 Month Change | -4.07% |
| 1 Year Change | -14.11% |
| 33 Year Change | -52.55% |
| 5 Year Change | -56.23% |
| Change since IPO | -63.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| O5O | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -2.8% | 2.9% | 1.1% |
| 1Y | -14.1% | 14.9% | 7.2% |
Return vs Industry: O5O underperformed the German Healthcare industry which returned 14.9% over the past year.
Return vs Market: O5O underperformed the German Market which returned 7.2% over the past year.
Price Volatility
| O5O volatility | |
|---|---|
| O5O Average Weekly Movement | 2.8% |
| Healthcare Industry Average Movement | 4.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: O5O has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: O5O's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 804 | Katarina Gabrielson | oriola.com |
Oriola Oyj provides healthcare and wellbeing products primarily in Sweden and Finland. It also offers vitamins, food and food supplements, sports nutrients, wound care, beauty, and makeup related products. In addition, it provides pharmaceutical logistics and dose dispensing services.
Oriola Oyj Fundamentals Summary
| O5O fundamental statistics | |
|---|---|
| Market cap | €166.05m |
| Earnings (TTM) | -€5.10m |
| Revenue (TTM) | €1.63b |
0.1x
P/S Ratio-32.4x
P/E RatioIs O5O overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| O5O income statement (TTM) | |
|---|---|
| Revenue | €1.63b |
| Cost of Revenue | €1.47b |
| Gross Profit | €159.30m |
| Other Expenses | €164.40m |
| Earnings | -€5.10m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 04, 2025
| Earnings per share (EPS) | -0.028 |
| Gross Margin | 9.79% |
| Net Profit Margin | -0.31% |
| Debt/Equity Ratio | 45.9% |
How did O5O perform over the long term?
See historical performance and comparison